Targeting the Mutant Region in K-RAS by RNA Interference Controlling Cell Proliferation and Programmed Cell Death in Liver Cancer Cells.

  • Dina Ali
  • Adel A. Guirgis
  • Hany Khalil Department of Molecular Biology, Genetic Engineering and Biotechnology Research Institute, University of Sadat City
Keywords: RNA interference; Hepatocellular carcinoma; k-ras gene; cell proliferation


Background Hepatocellular carcinoma (HCC) is a high-incidence and significant cause of cancer globally. HCC is the world's third most common death-related cancer and the sixth most common tumor. In HCC, various cellular signaling is activated to ensure malignancy transformation, angiogenesis, and metastasis. The most efficient signaling pathway in cancer is mitogen-activated protein kinase (MAPK), which controls malignancy and regulates apoptosis. The mutant k-ras gene led to the activation of the RAS protein with GTPase activity, which stimulated hepatocellular proliferation and transformation. Here we aim to investigate the correlation between the knock-down of k-ras and HCC evaluation in-vitro. 

Material and Methods We used the HepG2 cell line to investigate the direct connection between the k-ras expression profile and RAF/MEK pathway using a respective siRNA antagonist k-ras

Results Interestingly, the siRNA antagonist k-ras altered cell morphology and a number of the living HepG2 cells. In addition, the transfection of HepG2 cells with the firstly designed siRNA successfully reduced the expression profile k-ras and the relative gene expression of Raf-1 and Mek1, the downstream targets of RAS signaling. Furthermore, interleukin 8 (IL-8) and interleukin 6 (IL-6) were monitored in the fluids media at different time points following transfection. Both IL-6 and Il-8 production significantly increased in cells transfected with siRNA targeting k-ras

Conclusion Our findings provide evidence for the influential role of the k-ras mutated gene in HCC development and suggest the possible regulation of this gene as a potential treatment for HCC.


Yang JD, Roberts LR, Epidemiology and Management of Hepatocellular Carcinoma. Infect. Dis. Clin. North Am. 2010, 24, 899–919.

Colagrande S., Inghilesi A.L., Aburas S., Taliani G.G., Nardi C., Marra F. 2016. Challenges of advanced hepatocellular carcinoma. World J. Gastroenterol. 22, 7645.

Takeda H, Takai A, Eso Y, Takahashi K, Marusawa H, Seno H. 2022. Genetic Landscape of Multistep Hepatocarcinogenesis. Cancers (Basel). 14.

Llovet J.M. et al. 2021. Hepatocellular carcinoma. Nat. Rev. Dis. Prim. 7.

El-Serag H.B. 2012. Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma. Gastroenterology. 142, 1264-1273.e1.

Davis GL, Dempster J, Meler JD, Orr DW, Walberg MW, Brown B, Berger BD, O’Connor JK, Goldstein RM. Hepatocellular Carcinoma: Management of an Increasingly Common Problem. Baylor Univ. Med. Cent. Proc. 2008, 21, 266–80.

Dhar D, Baglieri J, Kisseleva T, Brenner DA. 2020. Mechanisms of liver fibrosis and its role in liver cancer. Exp. Biol. Med. 2020, 245, 96–108.

Bouchard MJ, Navas-Martin S. Hepatitis B and C virus hepatocarcinogenesis: Lessons learned and future challenges. Cancer Lett. 2011,305, 123–43.

Khalil H, Arfa M, El-Masrey S, EL-Sherbini S, Abd-Elaziz A. Single nucleotide polymorphisms of interleukins associated with hepatitis C virus infection in Egypt. J. Infect. Dev. Ctries. 2017, 11, 261–8.

Khalil H. The Intracellular Signalling that Associated with Influenza a Virus Infection. Pediatr. Infect. Dis. 2017, 1, 38.

Pylayeva-Gupta Y., Grabocka E., Bar-Sagi D. RAS oncogenes: Weaving a tumorigenic web. Nat. Rev. Cancer. 2011, 11, 761–74.

Fernández-Medarde A, Santos E. 2011. Ras in cancer and developmental diseases. Genes and Cancer.

Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct. Target. Ther. 2021, 6, 386.

Abd El Maksoud AI, Taher RF, Gaara AH, Abdelrazik E, Keshk OS, Elawdan KA, Morsy SE, Salah A, Khalil H. Selective Regulation of B-Raf Dependent K-Ras/Mitogen-Activated Protein by Natural Occurring Multi-kinase Inhibitors in Cancer Cells. Front. Oncol. 2019, 9.

Moon H, Ro RW. MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma. Cancers (Basel). 2021, 13.

Yang S., Liu G. Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma (Review). Oncol Lett. 2017, 13, 1041–7.

Chen X, Mangala LS, Rodriguez-Aguayo C, Kong X, Lopez-Berestein G, Sood AK. RNA interference-based therapy and its delivery systems. Cancer Metastasis Rev. 2018, 37, 107–24.

El-Fadl HMA, et al. Effective Targeting of Raf-1 and Its Associated Autophagy by Novel Extracted Peptide for Treating Breast Cancer Cells. Front. Oncol. 2021, 11, 3317.

Abd El Maksoud AI, Elebeedy D., Abass N.H., Awad A.M., Nasr G.M., Roshdy T., Khalil H. 2020. Methylomic Changes of Autophagy-Related Genes by Legionella Effector Lpg2936 in Infected Macrophages. Front. Cell Dev. Biol. 7, 390.

Hamouda RA, Abd El Maksoud A.I., Wageed M., Alotaibi A.S., Elebeedy D., Khalil H., Hassan A., Abdella A. 2021. Characterization and Anticancer Activity of Biosynthesized Au/Cellulose Nanocomposite from Chlorella vulgaris. Polymers (Basel). 13.

Mohamed E-SA, Bassiouny K, Alshambky AA, Khalil H. Anticancer Properties of N,N-dibenzylasparagine as an Asparagine (Asp) analog, Using Colon Cancer Caco-2 Cell Line. Asian Pacific J. Cancer Prev. 2022, 23, 2531–40.

Khalil H, Arfa M, El-Masrey S, EL-Sherbini S, Abd-Elaziz A. Single nucleotide polymorphisms of interleukins associated with hepatitis C virus infection in Egypt. J. Infect. Dev. Ctries. 2017, 11, 261–8.

Rao X, Huang X, Zhou Z, Lin X. 2013. An improvement of the2–delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat Bioinforma Biomath.

Jančík S, Drábek J, Radzioch D, Hajdúch M. Clinical Relevance of KRAS in Human Cancers. Ed D. Fan. J. Biomed. Biotechnol. 2010, 150960.

Takács T, Kudlik G, Kurilla A, Szeder B, Buday L, Vas V. The effects of mutant Ras proteins on the cell signalome. Cancer Metastasis Rev. 2020, 39, 1051–65.

Chen K, Zhang Y, Qian L, Wang P. Emerging strategies to target RAS signaling in human cancer therapy. J. Hematol. Oncol. 2021, 14, 116.

Cefalì M, Epistolio S, Palmarocchi MC, Frattini M, Dosso SDe. Research progress on KRAS mutations in colorectal cancer. Res. Prog. KRAS Mutat. Color. cancer. 2021, 7, 26.

Rašková M. et al. The Role of IL-6 in Cancer Cell Invasiveness and Metastasis—Overview and Therapeutic Opportunities. Cells. 2022, 11.

Hsu P-C, Chen Y-H, Cheng C-F, Kuo C-Y, Sytwu H-K. Interleukin-6 and Interleukin-8 Regulate STAT3 Activation Migration/Invasion and EMT in Chrysophanol-Treated Oral Cancer Cell Lines. Life. 2021, 11.

Turner MD, Nedjai B, Hurst T, Pennington DJ. Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. Biochim. Biophys. Acta - Mol. Cell Res. 2014, 1843, 2563–82.

How to Cite
Ali, D., Guirgis, A. A., & Khalil, H. (2023). Targeting the Mutant Region in K-RAS by RNA Interference Controlling Cell Proliferation and Programmed Cell Death in Liver Cancer Cells. Journal of Internal Medicine: Science & Art, 4, 19 - 25.